Top

Published in:

Open Access 01-04-2016 | Research Paper

Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Authors: N. R. Sluiter, E. M. V. de Cuba, R. Kwakman, W. J. H. J. Meijerink, P. M. Delis-van Diemen, V. M. H. Coupé, J. A. M. Beliën, G. A. Meijer, I. H. J. T. de Hingh, E. A. te Velde

Published in: Clinical & Experimental Metastasis | Issue 4/2016

Abstract

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can increase survival of colorectal cancer (CRC) patients with peritoneal metastases (PM). This treatment is associated with high morbidity and mortality rates. Therefore, improvement of patient selection is necessary. Assuming that the clinical phenotype is dictated by biological mechanisms, biomarkers could play a crucial role in this process. Since it is unknown whether and to what extent angiogenesis influences the course of disease in patients with PM, we investigated the expression of two angiogenesis-related markers and their relation to overall survival (OS) in CRC patients after CRS and HIPEC. Clinicopathological data and tissue samples were collected from 65 CRC patients with isolated metastases to the peritoneum that underwent CRS and HIPEC. Whole tissue specimens from PM were evaluated for versican (VCAN) expression, VEGF expression and microvessel density (MVD) by immunohistochemistry. The relation between these markers and OS was assessed using univariate and multivariate analysis. Associations between VEGF expression, VCAN expression, MVD and clinicopathological data were tested. High stromal VCAN expression was associated with high MVD (p = 0.001), better resection outcome (p = 0.003) and high T-stage (p = 0.027). High epithelial VCAN expression was associated with MVD (p = 0.007) and a more complete resection (p < 0.001). In multivariate analysis, simplified peritoneal cancer index (p = 0.001), VEGF expression levels (p = 0.012), age (p = 0.030), epithelial VCAN expression levels (p = 0.042) and lymph node status (p = 0.053) were associated with OS. Concluding, VCAN and VEGF were associated with survival in CRC patients with PM after CRS and HIPEC. Independent validation in a well-defined patient cohort is required to confirm the putative prognostic role of these candidate biomarkers.

Available only for authorised users

Sugarbaker PH (1995) Patient selection and treatment of peritoneal carcinomatosis from colorectal and appendiceal cancer. World J Surg 19:235–240. doi:10.1007/BF00308632 CrossRefPubMed

Sugarbaker PH, Jablonski KA (1995) Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 221:124–132. doi:10.1097/00000658-199502000-00003 CrossRefPubMedPubMedCentral

Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z (2009) A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis 24:677–685. doi:10.1007/s00384-009-0655-9 CrossRefPubMed

Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63–68. doi:10.1200/JCO.2009.23.9285 CrossRefPubMed

Kuijpers AM, Mirck B, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, van Ramshorst B, van Ginkel RJ, Havenga K, Bremers AJ, de Wilt JH, Te Velde EA, Verwaal VJ, Kuijpers AM, Mirck B, Aalbers AG et al (2013) Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol 20:4224–4230. doi:10.1245/s10434-013-3145-9 CrossRefPubMedPubMedCentral

Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743. doi:10.1200/JCO.2003.04.187 CrossRefPubMed

Verwaal VJ, Kusamura S, Baratti D, Deraco M (2008) The eligibility for local-regional treatment of peritoneal surface malignancy. J Surg Oncol 98:220–223. doi:10.1002/jso.21060 CrossRefPubMed

de Cuba EM, Kwakman R, Knol DL, Bonjer HJ, Meijer GA, Te Velde EA (2013) Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev 39:321–327. doi:10.1016/j.ctrv.2012.11.003 CrossRefPubMed

Maggiori L, Bretagnol F, Ferron M, Chevalier Y, Panis Y (2011) Laparoscopic colorectal anastomosis using the novel Chex((R)) circular stapler: a case-control study. Colorectal Dis 13:711–715. doi:10.1111/j.1463-1318.2010.02246.x CrossRefPubMed

10.

Verwaal VJ, Zoetmulder FA (2004) Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 30:280–285. doi:10.1016/j.ejso.2003.12.003 CrossRefPubMed

11.

de Cuba EM, Kwakman R, van Egmond M, Bosch LJ, Bonjer HJ, Meijer GA, te Velde EA (2012) Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkers. Virchows Arch 461:231–243. doi:10.1007/s00428-012-1287-y CrossRefPubMed

12.

Taflampas P, Dayal S, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ (2014) Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: analysis of 519 patients. Eur J Surg Oncol 40:515–520. doi:10.1016/j.ejso.2013.12.021 CrossRefPubMed

13.

Pietras K, Ostman A (2010) Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 316:1324–1331. doi:10.1016/j.ejso.2013.12.021 CrossRefPubMed

14.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013 CrossRefPubMed

15.

Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127:679–695. doi:10.1016/j.cell.2006.11.001 CrossRefPubMed

16.

Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458. doi:10.1038/nrc1098 CrossRefPubMed

17.

Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:10931–10934PubMed

18.

Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V (2008) Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319:195–198. doi:10.1126/science.1150224 CrossRefPubMed

19.

de Cuba EMV, de Hingh IHJT, Sluiter NR, Kwakman R, Coupé VMH, Beliën JAM, Verwaal VJ, Meijerink WJHJ, Delis-van Diemen PM, Bonjer HJ, Meijer GA, te Velde EA (2016) Angiogenesis-related markers and prognosis after Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy for metastatic colorectal cancer. Ann Surg Oncol. doi:10.1245/s10434-015-5023-0 PubMed

20.

Logan-Collins JM, Lowy AM, Robinson-Smith TM, Kumar S, Sussman JJ, James LE, Ahmad SA (2008) VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol 15:738–744. doi:10.1245/s10434-007-9699-7 CrossRefPubMed

21.

Du WW, Yang W, Yee AJ (2013) Roles of versican in cancer biology–tumorigenesis, progression and metastasis. Histol Histopathol 28:701–713PubMed

22.

Ang LC, Zhang Y, Cao L, Yang BL, Young B, Kiani C, Lee V, Allan K, Yang BB (1999) Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain. J Neuropathol Exp Neurol 58:597–605. doi:10.1079/00005072-199906000-0004 CrossRefPubMed

23.

Labropoulou VT, Theocharis AD, Ravazoula P, Perimenis P, Hjerpe A, Karamanos NK, Kalofonos HP (2006) Versican but not decorin accumulation is related to metastatic potential and neovascularization in testicular germ cell tumours. Histopathology 49:582–593. doi:10.1111/j.1365-2559.2006.02558.x CrossRefPubMed

24.

Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS, Mok SC (2010) Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol Oncol 119:114–120. doi:10.1016/j.ygyno.2010.05.029 CrossRefPubMedPubMedCentral

25.

Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, Seshadri R, LeBaron RG, Horsfall DJ (2002) Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 8:1054–1060PubMed

26.

Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, LeBaron RG, Raymond WA, Tilley WD, Horsfall DJ (2004) Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 10:2491–2498. doi:10.1158/1078-0432.CCR-03-0146 CrossRefPubMed

27.

Du WW, Yang BB, Shatseva TA, Yang BL, Deng Z, Shan SW, Lee DY, Seth A, Yee AJ (2010) Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling. PLoS One 5:e13828. doi:10.1371/journal.pone.0013828 CrossRefPubMedPubMedCentral

28.

Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwiwat S, Byers S, Marshall VR, Tilley WD, Horsfall DJ (2007) Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem 282:10814–10825. doi:10.1074/jbc.M606991200 CrossRefPubMed

29.

Kusumoto T, Kodama J, Seki N, Nakamura K, Hongo A, Hiramatsu Y (2010) Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol Rep 23:917–925. doi:10.3892/or_00000715 PubMed

30.

Casey RC, Oegema TRJ, Skubitz KM, Pambuccian SE, Grindle SM, Skubitz APN (2003) Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells. Clin Exp Metastasis 20:143–152. doi:10.1023/A:1022670501667 CrossRefPubMed

31.

Lancaster JM, Dressman HK, Clarke JP, Sayer RA, Martino MA, Cragun JM, Henriott AH, Gray J, Sutphen R, Elahi A, Whitaker RS, West M, Marks JR, Nevins JR, Berchuck A (2006) Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 16:1733–1745. doi:10.1111/j.1525-1438.2006.00660.x CrossRefPubMed

32.

Fu Y, Nagy JA, Brown LF, Shih SC, Johnson PY, Chan CK, Dvorak HF, Wight TN (2011) Proteolytic cleavage of versican and involvement of ADAMTS-1 in VEGF-A/VPF-induced pathological angiogenesis. J Histochem Cytochem 59:463–473. doi:10.1369/0022155411401748 CrossRefPubMedPubMedCentral

33.

Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS, Yang BB (2004) Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 18:754–756. doi:10.1096/fj.03-0545fje PubMed

34.

Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA (2005) Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 12:65–71. doi:10.1007/s10434-004-1167-z CrossRefPubMed

35.

Kerkhof MH, Ruiz-Zapata AM, Bril H, Bleeker MC, Belien JA, Stoop R, Helder MN (2014) Changes in tissue composition of the vaginal wall of prementopausal women with prolapse. Am J Obstet Gynecol 210:168.e1-9. doi:10.1016/j.ajog.2013.10.881 CrossRefPubMed

36.

Breslow N (1970) A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika 57:579–594. doi:10.1093/biomet/57.3.579 CrossRef

37.

de Wit M, Belt EJ, Delis-van Diemen PM, Carvalho B, Coupé VM, Stockmann HB, Bril H, Beliën JA, Fijneman RJ, Meijer GA (2013) Lumican and versican are associated with good outcome in stage II and III colon cancer. Ann Surg Oncol 20(Suppl 3):S348–S359. doi:10.1245/s10434-012-2441-0 CrossRefPubMed

38.

Read JT, Rahmani M, Boroomand S, Allahverdian S, McManus BM, Rennie PS (2007) Androgen receptor regulation of the versican gene through an androgen response element in the proximal promoter. J Biol Chem 282:31954–31963. doi:10.1074/jbc.M702099200 CrossRefPubMed

39.

Portilla AG, Shigeki K, Dario B, Marcello D (2008) The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol 98(4):228–231. doi:10.1002/jso.21068 CrossRefPubMed

40.

Williams E, Martin S, Moss R, Durrant L, Deen S (2012) Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival. Virchows Arch 461(1):33–39CrossRefPubMed

41.

Shaheen RM, Ahmad SA, Liu W, Reinmuth N, Jung YD, Tseng WW et al (2001) Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 85(4):584–589. doi:10.1054/bjoc.2001.1936 CrossRefPubMedPubMedCentral

42.

Imaizumi T, Aoyagi K, Miyagi M, Shirouzu K (2010) Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model. Surg Today 40(9):851–857CrossRefPubMed

43.

Bai Y, Deng H, Yang Y, Zhao X, Wei Y, Xie G et al (2009) VEGF-targeted short hairpin RNA inhibits intraperitoneal ovarian cancer growth in nude mice. Oncology 77(6):385–394. doi:10.1159/000279385 CrossRefPubMed

44.

Diniz Bizzo SM, Meira DD, Lima JM, Mororó JDS, Casali-da-Rocha JC, Ornellas MHF (2010) Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer. Int J Gynaecol Obstet 109(2):113–117. doi:10.1016/j.ijgo.2009.11.021 CrossRefPubMed

45.

Varghese S, Burness M, Xu H, Beresnev T, Pingpank J, Alexander HR (2007) Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. Ann Surg Oncol 14(12):3460–3471. doi:10.1245/s10434-007-9557-7 CrossRefPubMed

46.

Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM (1999) Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6(4):373–378. doi:10.1007/s10434-999-0373-0 CrossRefPubMed

47.

Yoshikawa T, Tsuburaya A, Miyagi Y, Sekiguchi H, Kimura M, Cho H, Kobayashi O (2006) Up-regulation of hypoxia-inducible factor-1 alpha and VEGF mRNAs in peritoneal dissemination of patients with gastric cancer. Anticancer Res 26(5B):3849–3853PubMed

48.

Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, Lord EM (2006) Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol 169(5):1739–1752. doi:10.2353/ajpath.2006.051222 CrossRefPubMedPubMedCentral

49.

Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D (2009) Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 14(12):1242–1251. doi:10.1634/theoncologist.2009-0109 CrossRefPubMed

50.

Ninomiya S, Inomata M, Tajima M, Ali AT, Ueda Y, Shiraishi N, Kitano S (2009) Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice. J Surg Res 154(2):196–202. doi:10.1016/j.jss.2008.08.017 CrossRefPubMed

51.

Shaheen RM, Tseng WW, Vellagas R, Liu W, Ahmad SA, Jung YD, Reinmuth N, Drazan KE, Bucana CD, Hicklin DJ, Ellis LM (2001) Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int J Oncol 18:221–226PubMed

52.

Klaver YLB, Leenders BJM, Creemers G-J, Rutten HJT, Verwaal VJ, Lemmens VEPP et al (2013) Addition of biological therapies to palliative chemotherapy prolongs survival in patients with peritoneal carcinomatosis of colorectal origin. Am J Clin Oncol 36(2):157–161. doi:10.3892/ijo.18.2.221 CrossRefPubMed

53.

Ceelen W, Van NY, Putte DV, Pattyn P (2014) Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ann Surg Oncol 21:3023–3028. doi:10.1245/s10434-014-3713-7 CrossRefPubMed

54.

Eveno C, Passot G, Goéré D, Soyer P, Gayat E, Glehen O, Elias D, Pocard M (2014) Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 21:1792–1800. doi:10.1245/s10434-013-3442-3 CrossRefPubMed

55.

Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277:3904–3923. doi:10.1111/j.1742-4658.2010.07800.x CrossRefPubMed

56.

Sheng W, Dong H, Lee DY, Lu WY, Yang BB (2007) Versican modulates gap junction intercellular communication. J Cell Physiol 211:213–219. doi:10.1002/jcp.20921 CrossRefPubMed

57.

Cattaruzza S, Schiappacassi M, Kimata K, Colombatti A, Perris R (2004) The globular domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells. FASEB J 18:779–781. doi:10.1096/fj.03-0660fje PubMed

58.

Du WW, Fang L, Yang W, Sheng W, Zhang Y, Seth A, Yang BB, Yee AJ (2012) The role of versican G3 domain in regulating breast cancer cell motility including effects on osteoblast cell growth and differentiation in vitro—evaluation towards understanding breast cancer cell bone metastasis. BMC Cancer 12:341. doi:10.1186/1471-2407-12-341 CrossRefPubMedPubMedCentral

59.

Wu Y, Wu J, Lee DY, Yee A, Cao L, Zhang Y, Kiani C, Yang BB (2005) Versican protects cells from oxidative stress-induced apoptosis. Matrix Biol 24:3–13. doi:10.1016/j.matbio.2004.11.007 CrossRefPubMed

60.

Wu Y, Chen L, Zheng PS, Yang BB (2002) beta 1-Integrin-mediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican. J Biol Chem 277:12294–12301. doi:10.1074/jbc.M110748200 CrossRefPubMed

61.

LaPierre DP, Lee DY, Li SZ, Xie YZ, Zhong L, Sheng W, Deng Z, Yang BB (2007) The ability of versican to simultaneously cause apoptotic resistance and sensitivity. Cancer Res 67:4742–4750. doi:10.1158/0008-5472.CAN-06-3610 CrossRefPubMed

62.

Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500–504. doi:10.1038/nature11183 CrossRefPubMedPubMedCentral

63.

Ween MP, Hummitzsch K, Rodgers RJ, Oehler MK, Ricciardelli C (2011) Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. Clin Exp Metastasis 28:113–125. doi:10.1007/s10585-010-9363-7 CrossRefPubMed

64.

Yee AJ, Akens M, Yang BL, Finkelstein J, Zheng PS, Deng Z, Yang B (2007) The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res 9:R47. doi:10.1186/bcr1751 CrossRefPubMedPubMedCentral

65.

Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF (1999) Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5:1041–1056PubMed

66.

Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst 94(12):883–893. doi:10.1093/jnci/94.12.883 CrossRefPubMed

67.

Chen L, Endler A, Shibasaki F (2009) Hypoxia and angiogenesis: regulation of hypoxia-inducible factors via novel binding factors. Exp Mol Med 41(12):849–857. doi:10.3858/emm.2009.41.12.103 CrossRefPubMedPubMedCentral

68.

Voutilainen K, Anttila M, Sillanpää S, Tammi R, Tammi M, Saarikoski S, Kosma VM (2003) Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int J Cancer 107:359–364. doi:10.1002/ijc.11423 CrossRefPubMed

69.

Kwakman R, de Cuba EM, de Winter JP, de Hingh IH, Delis-van Diemen PM, Tijssen M, Rooimans MA, Krijgsman O, Carvalho B, Peters GJ, Bonjer HJ, Meijer GA, Te Velde EA (2015) Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival. Br J Cancer 112(5):851–856. doi:10.1038/bjc.2015.18 CrossRefPubMedPubMedCentral

Title: Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Authors: N. R. Sluiter
E. M. V. de Cuba
R. Kwakman
W. J. H. J. Meijerink
P. M. Delis-van Diemen
V. M. H. Coupé
J. A. M. Beliën
G. A. Meijer
I. H. J. T. de Hingh
E. A. te Velde
Publication date: 01-04-2016
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 4/2016
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-016-9779-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Repositioning “old” drugs for new causes: identifying new inhibitors of prostate cancer cell migration and invasion

Metformin may protect nondiabetic breast cancer women from metastasis

β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases

MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by down-regulating Rab27B and SRR, respectively

Characterization of passive permeability at the blood–tumor barrier in five preclinical models of brain metastases of breast cancer

Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer